CCR5 inhibitor cenicriviroc shows good activity against HIV; new formulation may reduce dropouts

The dual CCR5/CCR2 inhibitor cenicriviroc demonstrated good antiviral activity and tolerability in a phase 2 clinical trial, according to a report at the 14th European AIDS Conference yesterday in Brussels.

http://www.aidsmap.com/CCR5-inhibitor-cenicriviroc-shows-good-activity-against-HIV-new-formulation-may-reduce-dropouts/page/2781639/